Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T

December 7, 2020

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases

September 17, 2020